INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (JUMP)
An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF).
Sponsor: Novartis Pharmaceuticals
Listed as NCT01493414, this PHASE3 trial focuses on Myelofibrosis and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 9 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — May 2019 [monthly]
Completed PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: No Longer Available → Completed · Phase: NA → PHASE3
-
Jul 2017 — Jan 2018 [monthly]
No Longer Available NA
Phase: PHASE4 → NA
-
Jan 2017 — Jul 2017 [monthly]
No Longer Available PHASE4
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Afula, Israel , Alcalá de Henares, Spain , Alessandria, Italy , Algiers, Algeria , Alicante, Spain , Ancona, Italy , Antwerp, Belgium , Arlon, Belgium , Aschaffenburg, Germany and 218 more locations